Titan Pharmaceuticals Inc
TTNP4.610USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.13MMarket Cap
LossP/E TTM
More Details of Titan Pharmaceuticals Inc Company
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Titan Pharmaceuticals Inc Info
Ticker SymbolTTNP
Company nameTitan Pharmaceuticals Inc
IPO dateJan 18, 1996
CEOMr. Weei Jye Chay
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJan 18
AddressSuite 505
CitySAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone14152444990
Websitehttps://www.titanpharm.com/
Ticker SymbolTTNP
IPO dateJan 18, 1996
CEOMr. Weei Jye Chay
Company Executives of Titan Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Weei Jye Chay
Mr. Weei Jye Chay
Company Secretary, Director
Company Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Weei Jye Chay
Mr. Weei Jye Chay
Company Secretary, Director
Company Secretary, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 3
Updated: Wed, Dec 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Blue Harbour Asset Management L.L.C
19.99%
Choong (Choon Hau)
18.16%
Chung (Jeffrey)
11.28%
DRW Securities, LLC
1.60%
UBS Financial Services, Inc.
0.04%
Other
48.94%
Shareholders
Shareholders
Proportion
Blue Harbour Asset Management L.L.C
19.99%
Choong (Choon Hau)
18.16%
Chung (Jeffrey)
11.28%
DRW Securities, LLC
1.60%
UBS Financial Services, Inc.
0.04%
Other
48.94%
Shareholder Types
Shareholders
Proportion
Individual Investor
29.44%
Corporation
19.99%
Investment Advisor
1.64%
Hedge Fund
0.04%
Other
48.90%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
36
44.54K
3.35%
-16.74K
2025Q2
40
414.53K
44.46%
-42.07K
2025Q1
46
436.25K
42.35%
-38.12K
2024Q4
45
429.27K
46.95%
-32.22K
2024Q3
46
432.62K
47.32%
-13.85K
2024Q2
51
448.01K
49.00%
-8.81K
2024Q1
52
447.94K
49.00%
-53.81K
2023Q4
49
450.14K
59.78%
+330.86K
2023Q3
57
298.19K
41.35%
-95.76K
2023Q2
53
281.88K
39.24%
-113.75K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Blue Harbour Asset Management L.L.C
265.91K
19.99%
+265.91K
--
Jul 18, 2025
Choong (Choon Hau)
241.53K
18.16%
--
--
Jul 18, 2025
Chung (Jeffrey)
150.09K
11.28%
+6.25K
+4.35%
Jul 18, 2025
UBS Financial Services, Inc.
3.43K
0.26%
+833.00
+32.11%
Jun 30, 2025
Corecap Advisors Inc
88.00
0.01%
--
--
Jun 30, 2025
BofA Global Research (US)
18.00
0%
--
--
Jun 30, 2025
Group One Trading, L.P.
12.00
0%
--
--
Jun 30, 2025
Osaic Holdings, Inc.
10.00
0%
-5.00
-33.33%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Nov 30, 2020
Merger
30→1
Nov 30, 2020
Merger
30→1
Date
Type
Ratio
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Nov 30, 2020
Merger
30→1
Nov 30, 2020
Merger
30→1
Nov 30, 2020
Merger
30→1
Nov 30, 2020
Merger
30→1
FAQs
Who are the top five shareholders of Titan Pharmaceuticals Inc?
The top five shareholders of Titan Pharmaceuticals Inc are:
Blue Harbour Asset Management L.L.C holds 265.91K shares, accounting for 19.99% of the total shares.
Choong (Choon Hau) holds 241.53K shares, accounting for 18.16% of the total shares.
Chung (Jeffrey) holds 150.09K shares, accounting for 11.28% of the total shares.
UBS Financial Services, Inc. holds 3.43K shares, accounting for 0.26% of the total shares.
Corecap Advisors Inc holds 88.00 shares, accounting for 0.01% of the total shares.
Blue Harbour Asset Management L.L.C holds 265.91K shares, accounting for 19.99% of the total shares.
Choong (Choon Hau) holds 241.53K shares, accounting for 18.16% of the total shares.
Chung (Jeffrey) holds 150.09K shares, accounting for 11.28% of the total shares.
UBS Financial Services, Inc. holds 3.43K shares, accounting for 0.26% of the total shares.
Corecap Advisors Inc holds 88.00 shares, accounting for 0.01% of the total shares.
What are the top three shareholder types of Titan Pharmaceuticals Inc?
The top three shareholder types of Titan Pharmaceuticals Inc are:
Blue Harbour Asset Management L.L.C
Choong (Choon Hau)
Chung (Jeffrey)
Blue Harbour Asset Management L.L.C
Choong (Choon Hau)
Chung (Jeffrey)
How many institutions hold shares of Titan Pharmaceuticals Inc (TTNP)?
As of 2025Q3, 36 institutions hold shares of Titan Pharmaceuticals Inc, with a combined market value of approximately 44.54K, accounting for 3.35% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -41.11%.
What is the biggest source of revenue for Titan Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Titan Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
